Vendor
6 FDA submission entries in this directory. This is not a count of distinct commercial offers.
Claim vendor profileEach entry is an FDA submission, not a distinct commercial offer. Inspect the exact record before comparing evidence, asking for a quote or planning an integration.
Prepare with a buyer guide:
Clinical guide links appear when this list contains a current reviewed example. They do not classify or endorse the other entries. All buyer guides · Compare exact records · Documented families
ScreenPoint Medical B.V.
Authorized purpose: Transpara 2.1.0 is a concurrent reading aid for physicians interpreting screening full-field digital mammography and digital breast tomosynthesis, providing region and examination scores to support review of suspicious breast findings.
Screenpoint Medical B.V.
Authorized purpose: Automatically determine volumetric breast density, breast volume, and an ACR BI-RADS 5th Edition breast-density category from compatible digital mammography and digital breast tomosynthesis data to aid healthcare professionals in assessing breast tissue composition; it is not a diagnostic aid.
ScreenPoint Medical B.V.
Authorized purpose: Concurrent reading aid for physicians interpreting screening FFDM/DBT to identify suspicious breast regions and estimate malignancy likelihood.
ScreenPoint Medical B.V.
Authorized purpose: Concurrent reading aid for physicians interpreting screening FFDM and DBT to identify suspicious regions and assess malignancy likelihood.
ScreenPoint Medical B.V.
Authorized purpose: Transpara version 1.6 is a concurrent screening aid for FFDM and DBT that presents suspicious-region marks, region scores from 0 to 100, and an exam score from 1 to 10 for physician review.
Screenpoint Medical B.V.
Authorized purpose: Transpara version 1.5 is a concurrent screening full-field digital mammography aid that presents suspicious-region marks and scores for physician review and cannot be used as the sole basis for interpretation.